Neo Ivy Capital Management Increases Stake in Avantor, Inc. $AVTR

Neo Ivy Capital Management lifted its position in Avantor, Inc. (NYSE:AVTR) by 69.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,414 shares of the company’s stock after acquiring an additional 97,042 shares during the quarter. Neo Ivy Capital Management’s holdings in Avantor were worth $2,963,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its position in Avantor by 119.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after purchasing an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC bought a new stake in shares of Avantor in the 2nd quarter valued at about $32,000. Osaic Holdings Inc. lifted its position in shares of Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after purchasing an additional 1,064 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Avantor by 172.1% during the third quarter. Farther Finance Advisors LLC now owns 3,709 shares of the company’s stock valued at $46,000 after purchasing an additional 2,346 shares in the last quarter. Finally, Spire Wealth Management bought a new position in shares of Avantor during the second quarter valued at approximately $47,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

More Avantor News

Here are the key news stories impacting Avantor this week:

• Neutral Sentiment: Barclays reaffirmed an “underweight” rating and set a $8.50 price target (small upside relative to the current price), signaling limited near-term upside and continued cautious analyst positioning. Barclays Reaffirmation
• Neutral Sentiment: A recent Yahoo Finance piece outlines how analysts are resetting fair-value targets for Avantor, documenting the shift in analyst views but not pointing to an immediate positive catalyst. How The Avantor Story Is Shifting
• Negative Sentiment: Unusually large put-option volume: investors bought ~94,708 puts (up ~1,582% vs. typical), indicating significant bearish positioning or hedging activity that can amplify downside volatility.
• Negative Sentiment: Zacks Research issued a wave of cuts to quarterly and full-year EPS estimates, downgraded multiple forward-quarter forecasts and assigned AVTR a “Strong Sell” / Zacks Rank #5 — a material negative read on near-term fundamentals and sentiment. Zacks Adds AVTR to Strong Sell List

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Evercore set a $10.00 price objective on shares of Avantor in a research note on Wednesday, February 11th. Stifel Nicolaus set a $10.00 target price on Avantor in a research report on Thursday, February 12th. TD Cowen reiterated a “hold” rating on shares of Avantor in a report on Thursday, February 12th. Wells Fargo & Company reduced their price target on Avantor from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Finally, Barclays restated an “underweight” rating and set a $8.50 price objective on shares of Avantor in a research note on Friday. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $11.80.

Insider Activity

In other Avantor news, Director Gregory L. Summe bought 100,000 shares of Avantor stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average cost of $9.40 per share, with a total value of $940,000.00. Following the transaction, the director directly owned 400,000 shares of the company’s stock, valued at approximately $3,760,000. This represents a 33.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gregory T. Lucier purchased 50,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was acquired at an average price of $9.16 per share, with a total value of $458,000.00. Following the completion of the purchase, the director owned 50,000 shares of the company’s stock, valued at $458,000. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.20% of the company’s stock.

Avantor Trading Down 4.0%

NYSE:AVTR opened at $8.18 on Friday. The stock has a market capitalization of $5.58 billion, a price-to-earnings ratio of -10.49, a PEG ratio of 3.34 and a beta of 0.97. Avantor, Inc. has a 52 week low of $8.14 and a 52 week high of $18.02. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $10.70 and a 200 day moving average of $11.86.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, February 11th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.01. Avantor had a negative net margin of 8.09% and a positive return on equity of 10.45%. The business had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. During the same period in the previous year, the company earned $0.27 earnings per share. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.770-0.830 EPS. As a group, sell-side analysts anticipate that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.